Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study
- 24 December 2024
- journal article
- research article
- Published by SAGE Publications in Palliative Medicine
- Vol. 39 (2) , 298-306
Abstract
Background: Xerostomia is a common and difficult symptom experienced by patients with cancer. Pilocarpine is a cholinergic agent that stimulates salivation. Aim: To assess the feasibility of conducting a N-of-1 trial to determine the efficacy of pilocarpine orally dissolving tablets in patients with xerostomia. Design: Double-blind, crossover, placebo-controlled N-of-1 trials of 5 mg pilocarpine tablets vs placebo. Each trial consisted of three 6-day cycles containing pilocarpine (3 days) and placebo (3 days) in random order. Setting/participants: Participants with advanced cancer and xerostomia (scoring >3 on an 11-point numerical rating scale) from any cause, were recruited from an inpatient and outpatient palliative care unit in Brisbane, Australia. Results: Eighteen people were recruited in 17 months. Nine withdrew, seven before or during the first 4 days. Three withdrew due to unacceptable side effects. Two participants met the definition of response (⩾2 point reduction in mean scores active vs placebo cycles). When assessing individual cycles, 15 out of 27 cycles (56%) met the definition of response. More people reported at least one mild episode during pilocarpine than placebo of nausea (6 vs 3), vomiting (3 vs 0) and sweating (3 vs 2). About 48% of adverse event classifications were reported in placebo cycles only. Conclusion: Recruitment to an N-of-1 trial for xerostomia is feasible but attrition was high (50%). Early dropout may have been due to the trial length, complexity, appropriateness or number of questionnaires. Adverse events were generally mild. Two of 10 participants were considered to have benefited from pilocarpine warranting ongoing treatment.Keywords
Funding Information
- Mater Foundation (Mater clinical research seeding grant)
This publication has 24 references indexed in Scilit:
- Recruiting participants to a randomized controlled trial testing an intervention in palliative cancer care – The perspectives of health care professionalsEuropean Journal of Oncology Nursing, 2017
- Salivary hypofunction: An update on aetiology, diagnosis and therapeuticsArchives of Oral Biology, 2015
- The Essential Guide to N-of-1 Trials in Health2015
- Validity, Reliability, and Responsiveness of a Digital Version of the Visual Analog ScaleJournal of Hand Therapy, 2011
- A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of lifeSupportive Care in Cancer, 2010
- Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD)Bone Marrow Transplantation, 2007
- Radiation‐induced xerostomia in patients with head and neck cancerCancer, 2006
- Assessing the clinical significance of change scores recorded on subjective outcome measuresJournal of Manipulative and Physiological Therapeutics, 2004
- Pilocarpine Tablets for the Treatment of Dry Mouth and Dry Eye Symptoms in Patients With Sjögren SyndromeA Randomized, Placebo-Controlled, Fixed-Dose, Multicenter TrialArchives of internal medicine (1960), 1999
- Effects of pilocarpine on salivary flow in patients with Sjo¨gren's syndromeOral Surgery, Oral Medicine, Oral Pathology, 1991